Aviragen Therapeutics (AVIR) Tops Q1 EPS by 2c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $570 thousand.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance